Evidence map›Paper›PMID 11932229›Full record

ReviewClinical microbiology reviews2002

Biofilms: survival mechanisms of clinically relevant microorganisms.

Rodney M Donlan, J William Costerton

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Clinical microbiology reviews, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05422144 (BIAKOS Antimicrobial Wound Cleanser and BIAKOS Antimicrobial Wound Gel), which is not on this map. Cited by 2,057 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2,057citing papers in PubMed, 5 pooled it
27.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05422144 nawithdrawnnot on this mapstarted 2024, after this paper: background citation

BIAKOS Antimicrobial Wound Cleanser and BIAKOS Antimicrobial Wound Gel: Providing Biofilm Prevention and Treatment Through Continuum of Care

TypeinterventionalSponsorRochal Industries LLCRan2024 to 2025Enrolled0ConditionsAcute WoundArmsAntimicrobial Skin & Wound Cleanser (AWC), Antimicrobial Wound Gel (AWG)
3 · Its place in the literature

Who cites it

2,057 citing papers in PubMed, 5 syntheses or guidelines pooled it, 6,480 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Effects of an Herbal Formulation Ethanolic Extract onPathogens (Basel, Switzerland) · 2026
    Article
  13. Microorganisms · 2026
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Identification ofMicroorganisms · 2026
    Article
  20. Review

1,997 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Rodney M DonlanCenters for Disease Control and Prevention, Atlanta, Georgia 30333, USA. rld8@cdc.gov
J William Costerton
Centers for Disease Control and Prevention · USMontana State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Though biofilms were first described by Antonie van Leeuwenhoek, the theory describing the biofilm process was not developed until 1978. We now understand that biofilms are universal, occurring in aquatic and industrial water systems as well as a large number of environments and medical devices relevant for public health. Using tools such as the scanning electron microscope and, more recently, the confocal laser scanning microscope, biofilm researchers now understand that biofilms are not unstructured, homogeneous deposits of cells and accumulated slime, but complex communities of surface-associated cells enclosed in a polymer matrix containing open water channels. Further studies have shown that the biofilm phenotype can be described in terms of the genes expressed by biofilm-associated cells. Microorganisms growing in a biofilm are highly resistant to antimicrobial agents by one or more mechanisms. Biofilm-associated microorganisms have been shown to be associated with several human diseases, such as native valve endocarditis and cystic fibrosis, and to colonize a wide variety of medical devices. Though epidemiologic evidence points to biofilms as a source of several infectious diseases, the exact mechanisms by which biofilm-associated microorganisms elicit disease are poorly understood. Detachment of cells or cell aggregates, production of endotoxin, increased resistance to the host immune system, and provision of a niche for the generation of resistant organisms are all biofilm processes which could initiate the disease process. Effective strategies to prevent or control biofilms on medical devices must take into consideration the unique and tenacious nature of biofilms. Current intervention strategies are designed to prevent initial device colonization, minimize microbial cell attachment to the device, penetrate the biofilm matrix and kill the associated cells, or remove the device from the patient. In the future, treatments may be based on inhibition of genes involved in cell attachment and biofilm formation.

Indexed as

BacteriaBacterial InfectionsBiofilmsCatheterizationContact LensesHumansProstheses and ImplantsProsthesis-Related Infections

Identifiers

PMID11932229
PMCPMC118068
OpenAlexW2131727615

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.